Identification, quantification and monitoring of circulating tumor DNA in peripheral blood in patients with diffuse large B-cell lymphoma using Z-Scan technique and cancer personalized profiling by deep sequencing (CAPP-Seq)

• Grant number: 19/10658-0
• Support Opportunities: Regular Research Grants
• Start date: August 01, 2019
• End date: July 31, 2022
• Field of knowledge: Physical Sciences and Mathematics - Physics - Atomic and Molecular Physics
• Principal Investigator: Juliana Pereira
• Grantee: Juliana Pereira
• Host Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Associated researchers: Débora Levy ; Fernando Luiz Affonso Fonseca ; Sarah Isabel Pinto Monteiro Do Nascimento Alves

Abstract

Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL) is the most common lymphoma subtype worldwide, and represents the eleventh most common form of cancer in Brazil. Because of its clinical and biological heterogeneity, rapid and accurate diagnosis is necessary to improve patient survival. It has been demonstrated that a technique called Z-Scan is able to determine the presence of circulating free tumor DNA (ctDNA) in peripheral blood in real time. Because of its highly specific and sensitive properties, Z-scan can accurately reflect tumor burden, helping in the diagnosisof neoplasms andin the monitoring of minimal residual disease (post-treatment control). Due to the unprecedented aspect of Z-scanas a method of identification and quantification of onco-hematological diseases, we will jointly perform a more consolidated and reliable technique to validate the observed results. For this, we will use the method called personalized profile of cancer by deep sequencing (CAPP-seq). We intend to implement an innovating technique based on thephysico-chemical properties of ctDNAas a fast, low cost, non-invasive, highly specific and sensible diagnostic tool for DLBCL to be used inBrazil's Public Health System (SUS). In addition, the technique can be used to monitor ctDNA as a biomarker for the early detection of slow, rapid and resistant responders to immunochemotherapy treatment. (AU)